CEOi

Lundbeck joins Global Alzheimer’s Platform

Monday, August 10, 2015

Lundbeck, a global pharmaceutical company specializing in brain disorders, has joined the Global Alzheimer’s Platform (GAP) to help accelerate the development of new treatments for Alzheimer’s disease. GAP is a research initiative that aims to reduce the time and costs of Alzheimer’s disease clinical trials, develop an infrastructure that promotes innovation, and assure international collaboration on Alzheimer’s disease treatments.

[Read More]

CEOi, NY Academy of Sciences to launch Global Alzheimer’s Platform

Wednesday, February 26, 2014

The Global CEO Initiative (CEOi) on Alzheimer’s Disease and the New York Academy of Sciences have convened representatives from industry, academia, government and nonprofits to launch the development of a Global Alzheimer’s Platform (GAP), designed to reduce the time and costs of Alzheimer’s clinical trials, develop an infrastructure that promotes innovation and assure international collaboration.

[Read More]